A Phase I, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic Human Papilloma Virus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC) after curative treatment.

Trial Profile

A Phase I, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic Human Papilloma Virus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC) after curative treatment.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs AMV-002 (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Admedus Immunotherapies
  • Most Recent Events

    • 31 Jan 2018 Status changed from planning to not yet recruiting.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top